Identification of miRNAs as non-invasive biomarkers for early diagnosis of lung cancers

Wang, Wenzhe; Li, Weili; Ding, Mingjian; Yuan, Haining; Yang, Jian; Meng, Wen; Jin, Er; Wang, Xiaoju; Ma, Shenglin

doi:10.1007/s13277-016-5442-y

Cited by 14 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining 216 articles were further checked by screening the full texts. Finally, a total of 134 studies from 65 articles including 13,983 samples (6,919 patients with lung cancer and 7,064 controls) were qualified for our analysis [ 11 – 75 ]. The process of article selection is summarized in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Most studies selected miRNAs by microarray [ 12 , 13 , 18 , 21 , 22 , 24 , 26 – 28 , 34 – 37 , 39 , 41 , 42 , 46 – 49 , 52 , 55 , 59 , 61 , 64 , 67 , 74 ]. Some identified miRNAs by literature [ 11 , 14 – 16 , 19 , 23 , 25 , 29 – 33 , 40 , 43 – 45 , 50 , 51 , 53 , 54 , 56 – 58 , 60 , 62 , 63 , 65 , 66 , 68 – 73 , 75 , 84 ]. To give an insight to future studies, we listed the potential miRNAs reported by literature that could serve as circulating biomarkers.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers

Yang

Zhou

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Many studies have investigated the diagnostic role of circulating microRNAs (miRNAs) in patients with lung cancer; however, the results still remain inconclusive. An updated system review and meta-analysis was necessary to give a comprehensive evaluation of diagnostic role of circulating miRNAs in lung cancer. Eligible studies were searched in electronical databases. The sensitivity and specificity were used to plot the summary receiver operator characteristic (SROC) curve and calculate the area under the curve (AUC). The between-study heterogeneity was evaluated by Q test and I2 statistics. Subgroup analyses and meta-regression were further performed to explore the potential sources of heterogeneity. A total of 134 studies from 65 articles (6,919 patients with lung cancer and 7,064 controls) were included for analysis. Overall analysis showed that circulating miRNAs had a good diagnostic performance in lung cancers, with a sensitivity of 0.83, a specificity of 0.84, and an AUC of 0.90. Subgroup analysis suggested that combined miRNAs and Caucasian populations may yield relatively higher diagnostic performance. In addition, we found serum might serve as an ideal material to detecting miRNA as good diagnostic performance. We also found the diagnostic role of miRNAs in early stage lung cancer was still relatively high (the sensitivity, specificity and an AUC of stage I/II was 0.81, 0.82 and 0.88; and for stage I, it was 0.80, 0.81, and 0.88). We also identified a panel of miRNAs such as miR-21-5p, miR-223-3p, miR-155-5p and miR-126-3p might serve as potential biomarkers for lung cancer. As a result, circulating miRNAs, particularly the combination of multiple miRNAs, may serve as promising biomarkers for the diagnosis of lung cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers

Yang

Zhou

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…A total of 98 studies were included in 29 articles, and the number of patients with LC was 2487, and the number of included controls was 1467. The main characteristics of the included articles are listed in Tables S1‐S4.…”

Section: Resultsmentioning

confidence: 99%

Could microRNA be used as a diagnostic tool for lung cancer?

Wang

Guan

Wang

2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Objectives Current methods for diagnosing lung cancer (LC) have varying degrees of risks and complications. MicroRNA (miRNA) is a small molecule noncoding RNA with gene regulation functions. Many studies have shown that miRNA can be used for the diagnosis of LC, but there are differences in diagnostic accuracy. Therefore, we aim to systematically review and meta‐analyze published articles to comprehensively evaluate the diagnostic value of miRNA for LC. Materials and methods We searched the PubMed, Embase, and Cochrane databases, and calculated the area under the curve (AUC) by plotting the summary receiver operator characteristic curve using the sensitivity and specificity of each included study. The AUC was calculated and the likelihood ratio was plotted to assess the diagnostic accuracy of miRNA. We used QUADAS‐2 in Review Manager 5.3 to evaluate the quality of all the articles. The other analyses were performed using the STATA 12.0 software. Results We included a total of 29 articles, 98 studies, and the qualities of all the articles were satisfactory. The overall pooled parameters calculated from all studies were as follows: sensitivity = 0.77, specificity = 0.83, positive likelihood ratio (PLR) = 4.6, negative likelihood ratio (NLR) = 0.28, and AUC = 0.87 for miRNA diagnosis. It had significant advantages over other biomarkers. Subgroup analysis showed that when combined four or more miRNA for the diagnosis of LC, the parameters were as follows: sensitivity = 0.90, specificity = 0.93, PLR = 13.2, NLR = 0.11, and AUC = 0.97. Conclusion Four or more miRNA combination could be used for the diagnosis of LC. Besides this, we also found that miRNA showed a greater advantage in distinguishing LC from benign lung diseases than distinguishing between LC and normal people. Our findings provided a new way of thinking about the clinical diagnosis of LC from a nonmorphological aspect.

show abstract

“…Fourteen of the 20 studies provided no information on comorbidity of the patient cohort; the other 6 studies indicated that patients had no history of other cancers ( Supplementary Table 1A ) [ 26 , 48 – 52 ]. A mix of the two main subtypes of NSCLC, AC and SCC, was present in all the selected papers, however only in 11 studies the accuracy of the miRNA profile of NSCLC was separately evaluated for AC and SCC [ 26 , 29 , 30 , 41 , 44 , 46 , 48 – 50 , 53 , 54 ]. The composition of control groups was also varied ( Supplementary Table 1A ).…”

Section: Resultsmentioning

confidence: 99%

Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

Selected circulating microRNAs (miRNAs) have been suggested for non-invasive screening of non-small cell lung cancer (NSCLC), however the numerous proposed miRNA signatures are inconsistent.Aiming to identify miRNAs suitable specifically for stage I-II NSCLC screening in serum/plasma samples, we searched the databases “Pubmed”, “Medline”, “Scopus”, “Embase” and “WOS” and systematically reviewed the publications reporting quantitative data on the efficacy [sensitivity, specificity and/or area under the curve (AUC)] of circulating miRNAs as biomarkers of NSCLC stage I and/or II. The 20 studies fulfilling the search criteria included 1110 NSCLC patients and 1009 controls, and were of medium quality according to Quality Assessment of Diagnostic Accuracy Studies checklist. In these studies, the patient cohorts as well as the control groups were heterogeneous for demographics and clinicopathological characteristics; moreover, numerous pre-analytical and analytical variables likely influenced miRNA determinations, and potential bias of hemolysis was often underestimated. We identified four circulating miRNAs scarcely influenced by hemolysis, each featuring high sensitivity (> 80%) and AUC (> 0.80) as biomarkers of stage I-II NSCLC: miR-223, miR-20a, miR-448 and miR-145; four other miRNAs showed high specificity (> 90%): miR-628-3p, miR-29c, miR-210 and miR-1244. In a model of two-step screening for stage I-II NSCLC using first the above panel of serum miRNAs with high sensitivity and high AUC, and subsequently the panel with high specificity, the estimated overall sensitivity is 91.6% and overall specificity is 93.4%. These and other circulating miRNAs suggested for stage I-II NSCLC screening require validation in multiple independent studies before they can be proposed for clinical application.

show abstract

Identification of miRNAs as non-invasive biomarkers for early diagnosis of lung cancers

Cited by 14 publications

References 27 publications

The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers

The clinical use of circulating microRNAs as non-invasive diagnostic biomarkers for lung cancers

Could microRNA be used as a diagnostic tool for lung cancer?

Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer

Contact Info

Product

Resources

About